MMMichael Maurer

Michael Maurer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Maurer has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ganoderma lucidum Extract Modulates Gene Expression Profiles Associated with Antioxidant Defense, Cytoprotection, and Senescence in Human Dermal Fibroblasts: Investigation of Quantitative Gene Expression by qPCR

    by Harald Kühnel, Markus Seiler, Barbara Feldhofer, Atefeh Ebrahimian, Michael Maurer

    Cellular senescence plays a crucial role in skin aging, with senescent dermal fibroblasts contributing to reduced skin elasticity and increased inflammation. This study investigated the potential of Ganoderma lucidum (Reishi) ethanol extract to modulate the senescent phenotype of human dermal fibroblasts. Reishi powder of two different vendors was used. The extract was produced by extracting the Reishi powder for at least three weeks in 40% ethanol at room temperature. Etoposide-induced senescent fibroblasts were treated with Reishi extracts from two commercial sources for 14 days. Gene expression analysis was performed using qPCR to assess senescence makers, antioxidant defense, and extracellular matrix remodeling. Results showed that Reishi extracts significantly upregulated antioxidant and cytoprotective genes, including Heme oxygenase 1 (HO-1), γ-Glutamylcysteine synthetase (γGCS-L), and NAD(P)H dehydrogenase [quinone] 1 (NQO1), compared to untreated controls. Importantly, Reishi treatment suppressed the expression of p16INK4a, a key marker of cellular senescence, while transiently upregulating p21Cip1. The extracts also demonstrated potential senolytic properties, reducing the percentage of senescent cells as measured by senescence-associated β-galactosidase staining. However, Reishi treatment did not mitigate the upregulation of MMP1 and IL-8 in one Reishi treatment group, indicating differences in the preparations of different vendors. These findings suggest that Ganoderma lucidum extract may help alleviate some aspects of cellular senescence in dermal fibroblasts, primarily through enhanced antioxidant defense and cytoprotection, potentially offering a novel approach to combat skin aging.


  • Open Access

    Ganoderma lucidum Extract Modulates Gene Expression Profiles Associated with Antioxidant Defense, Cytoprotection, and Senescence in Human Dermal Fibroblasts: A Transcriptomic Analysis

    by Harald Kühnel, Markus Seiler, Atefeh Ebrahimian, Barbara Feldhofer, Michael Maurer

    Cellular senescence plays a crucial role in skin aging, with senescent dermal fibroblasts contributing to reduced skin elasticity and increased inflammation. This study investigated the potential of Ganoderma lucidum (Reishi) extract to modulate the senescent phenotype of human dermal fibroblasts. Etoposide-induced senescent fibroblasts were treated with Reishi extracts from two commercial sources for 14 days. Gene expression analysis was performed using qPCR to assess markers of senescence, antioxidant defense, and extracellular matrix remodeling. Results showed that Reishi extracts significantly upregulated antioxidant and cytoprotective genes, including HO-1, γGCS-L, and NQO1, compared to untreated controls. Importantly, Reishi treatment suppressed the expression of p16, a key marker of cellular senescence, while transiently upregulating p21. The extracts also demonstrated potential senolytic properties, reducing the percentage of senescent cells as measured by SA-β-Gal staining. However, Reishi treatment did not mitigate the upregulation of matrix metalloproteinase-1 (MMP1) induced by senescence. These findings suggest that Ganoderma lucidum extract may help alleviate some aspects of cellular senescence in dermal fibroblasts, primarily through enhanced antioxidant defense and cytoprotection, potentially offering a novel approach to combat skin aging.

  • Open Access

    Exploring Senolytic and Senomorphic Properties of Medicinal Plants for Anti-Aging Therapies

    by Monika Imb, Zsolt Véghelyi, Michael Maurer, Harald Kühnel

    Senolytic and senomorphic therapies have gained more and more attention in the last decade. This kind of therapy is based on the killing of cellular senescent cells without harming the “normal” cells. Aging is not a disease. Clinical studies on healthy people will be difficult to conduct. Therefore, one possibility is to draw on the large repertoire of medicinal plants and use their senolytic properties to provide mild anti-aging therapies. Chamomile, goldenrod, reishi, and green tea were tested for their ability to trigger senolysis. Quercetin was used as control substance. Cellular senescence was induced with 25 µM etoposide in human dermal fibroblasts and established for at least 14 days. The plant extracts were tested for their antioxidant potential (DPPH assay) and their polyphenol content. Senolysis was determined by presto blue assay of young and etoposide-induced senescent cells, and SA-β-Gal assays were also performed. The senomorphic properties of the plants were investigated using IL-6 ELISA and qPCR. It turned out that chamomile triggers a kind of cytokine storm and causes the cytokine values in the ELISA and in the qPCR to rise extremely, and other senescence-associated phenotype (SASP) markers were also elevated. Goldenrod and quercetin tend to have a senolytic and senomorphic effect, respectively. Regarding the senolytic and senomorphic properties of herbs, we found that all tested herbs can have a senolytic effect, and a senomorphic effect of quercetin has also been discovered. With regard to the effect of chamomile, however, we can say that seemingly harmless tea products may have harmful effects, especially in combination with chemotherapy, at least in cell culture experiments. Nevertheless, inflammation is a double-bladed mechanism with positive effects, for example, in healing, but also known negative effects.


  • Open Access

    Parameter Optimization and Capacitance-Based Monitoring of In Situ Cell Detachment in Microcarrier Cultures

    by Atefeh Ebrahimian, Mona Schalk, Mark Dürkop, Michael Maurer, Rudolf Bliem, Harald Kühnel

    This study delves into the scale-down optimization of the in situ cell detachment process for MA 104 cells cultivated on Cytodex 1 microcarriers (MCs). Through a systematic exploration, critical operational parameters—the agitation speed, incubation time, Trypsin–EDTA volume and corresponding activity, and washing steps—were identified as key factors influencing the efficiency and scalability of in situ cell detachment in microcarrier-based cell culture. Maintaining an appropriate agitation speed (1.25 × Njs, minimum agitation speed at which no microcarriers remain stationary for the signification period of 5 s), optimizing the Trypsinization incubation time (up to 60 min), and implementing multiple washing steps (two times) post-medium removal were found to be crucial for efficient cell detachment and subsequent growth. Our study demonstrates the feasibility of reducing the final Trypsin volume to 50 mL per gram of microcarrier while maintaining a Trypsin activity above 380 USP/mL. These conditions ensure complete cell dissociation and improve the cost effectiveness in large-scale productions. Additionally, we introduced real-time monitoring using a capacitance sensor during in situ cell detachment. This method has proven to be an effective process analytical technology (PAT) tool for tracking the cell detachment progress and efficiency. It allows for the prediction of cell detachment based on signals recorded between 3 and 7 min of Trypsinization, enabling rapid process decisions without the need for offline sampling, thereby enhancing the overall process control. This systematic approach not only optimizes in situ cell detachment processes but also has significant implications for the scalability and efficiency of microcarrier-based cell culture systems.


  • Open Access

    Exploring Senolytic and Senomorphic Properties of Medicinal Plants for Anti-Aging Therapies

    by Monika Imb, Zsolt Véghelyi, Michael Maurer, Harald Kühnel

    Senolytic and senomorphic therapies gain more and more attention in the last decade. This kind of therapy is based on the killing of cellular senescent cells without harming the “normal” cells. Ageing is not a disease. Clinical studies on healthy people will be difficult to conduct. Therefore, one possibility is to draw on the large repertoire of medicinal plants and use their sneolytic properties to provide mild, anti-ageing therapies. Chamomile, goldenrod, reishi and green tea were tested for their ability to trigger senolysis quercetin was used as control substance. Cellular senescence was induced with 25µM etoposide in human dermal fibroblasts and established for at least 14 days. The plant extracts were tested for their antioxidant potential (DPPH assay) and their polyphenol content. Senolysis was determined by presto blue assay of young and etoposide-induced senescent cells, and ß-Gal assays were also performed. The senomporphic properties of the plants were investigated using IL-6 ELISA and qPCR. It turned out that chamomile triggers a kind of cytokine storm and causes the cytokine values in the Elisa and in the qPCR to rise extremely, and other senescence-associated phenotype (SASP) markers were also elevated. Goldenrod and quercetin tend to have a senolytic and senomorphic effect respectively. Regarding the senolytic and senomorphic properties of herbs, we have found that all tested herbs can have a senolytic effect, and a senomorphic effect of quercetin has also been uncovered. With regard to the effect of chamomile, however, we can say that seemingly harmless tea products may have harmful effects, especially in combination with chemotherapy, at least in cell culture experiments.


  • Open Access

    Seed Train Optimization in Microcarrier-Based Cell Culture Post In Situ Cell Detachment through Scale-Down Hybrid Modeling

    by Atefeh Ebrahimian, Mona Schalk, Mark Dürkop, Michael Maurer, Rudolf Bliem, Harald Kühnel

    Microcarrier-based cell culture is a commonly used method to facilitate the growth of anchorage-dependent cells like MA 104 for antigen manufacturing. However, conventionally, static cell culture is employed for cell propagation before seeding the production bioreactor with microcarriers (MCs). This study demonstrates the effective replacement of the conventional method by serial subculturing on MCs with in situ cell detachment under optimal conditions in closed culture units. This study proves that MA 104 can be subcultured at least five times on Cytodex 1 MC without the need for separating cells and MC after cell harvest. Process parameters impacting cell growth were studied post in situ cell detachment in a scaled-down model. Optimization, using augmented Design of Experiments (DoE) combined with hybrid modeling, facilitated rapid screening of the design space for critical process parameters (CPPs). Optimized conditions included an inoculation density of >16 cells/bead, 3.5–4.5 g/L of Cytodex 1, and a controlled agitation speed, starting at Njs (minimum agitation speed) for the first day with a maximum increase of 25% thereafter. With these design spaces for CPPs, a cell density of 2.6 ± 0.5 × 106 cells/mL was achieved after five days. This refined bioprocess methodology offers a reliable and efficient approach for seed training in stirred tank reactors, which is particularly beneficial for viral vaccine production.


  • IGF1 inclusion bodies: A QbD based process approach for efficient USP as well as early DSP unit operations

    by Karl F.J. Metzger, Wolfgang Padutsch, Alexander Pekarsky, Julian Kopp, Alexei M. Voloshin, Harald Kühnel, Michael Maurer


  • Adsorptive filtration: A case study for early impurity reduction in an Escherichia coli production process

    by Karl F.J. Metzger, Alexei Voloshin, Harald Schillinger, Harald Kühnel, Michael Maurer

    Primary recovery of intracellular products from Escherichia coli requires cell disruption which leads to a massive release of process‐related impurities burdening subsequent downstream process (DSP) unit operations. Especially, DNA and endotoxins challenge purification operations due to their size and concentrations. Consequently, an early reduction in impurities will not only simplify the production process but also increase robustness while alleviating the workload afterward. In the present work, we studied the proof of concept whether a nonwoven anion exchange filter material decreases soluble impurities immediately at the clarification step of E. coli DSP. In a first attempt, endotoxin burden was reduced by 4.6‐fold and the DNA concentration by 3.6‐fold compared to conventional depth filtration. A design of experiment for the adsorptive filtration approach was carried out to analyze the influence of different critical process parameters (CPPs) on impurity reduction. We showed that depending on the CPPs chosen, a DNA lowering of more than 3 log values, an endotoxin decrease of approximately 7 logs, and a minor HCP clearance of at least 0.3 logs could be achieved. Thus, we further revealed a chromatography column protecting effect when using adsorptive filtration beforehand.


  • Primary Recovery of Yeast Culture Supernatant for Recombinant Protein Purification

    by Michael M. Maurer, Harald Schillinger

    The harvest of a bench scale high cell density fermentation of Pichia pastoris, using standard laboratory equipment, to process products from supernatant is described. The process consists of a centrifugation step and a depth filtration, followed by a (sterile) membrane filtration. The procedure yields supernatant ready for the next purification step such as chromatography.


  • Open Access

    Induction without methanol: novel regulated promoters enable high-level expression in Pichia pastoris

    by Roland Prielhofer, Michael Maurer, Joachim Klein, Jana Wenger, Christoph Kiziak, Brigitte Gasser, Diethard Mattanovich

    Background: Inducible high-level expression is favoured for recombinant protein production in Pichia pastoris. Therefore, novel regulated promoters are desired, ideally repressing heterologous gene expression during initial growth and enabling it in the production phase. In a typical large scale fed-batch culture repression is desired during the batch phase where cells grow on a surplus of e.g. glycerol, while heterologous gene expression should be active in the feed phase under carbon (e.g. glucose) limitation. Results: DNA microarray analysis of P. pastoris wild type cells growing in glycerol-based batch and glucose-based fed batch was used for the identification of genes with both, strong repression on glycerol and high-level expression in the feed phase. Six novel glucose-limit inducible promoters were successfully applied to express the intracellular reporter eGFP. The highest expression levels together with strong repression in pre-culture were achieved with the novel promoters PG1 and PG6. Human serum albumin (HSA) was used to characterize the promoters with an industrially relevant secreted protein. A PG1 clone with two gene copies reached about 230% of the biomass specific HSA titer in glucose-based fed batch fermentation compared to a PGAP clone with identical gene copy number, while PG6 only achieved 39%. Two clones each carrying eleven gene copies, expressing HSA under control of PG1 and PG6 respectively were generated by post-transformational vector amplification. They produced about 1.0 and 0.7 g L-1 HSA respectively in equal fed batch processes. The suitability in production processes was also verified with HyHEL antibody Fab fragment for PG1 and with porcine carboxypeptidase B for PG6. Moreover, the molecular function of the gene under the control of PG1 was determined to encode a high-affinity glucose transporter and named GTH1. Conclusions: A set of novel regulated promoters, enabling induction without methanol, was successfully identified by using DNA microarrays and shown to be suitable for high level expression of recombinant proteins in glucose-based protein production processes.